GlassScriptPhysician profile
Lea Marie Pace
NPI 1710211180
$1,929.97
in general payments reported to CMS, 2019-2025
21 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $617 · 2022: $389 · 2023: $336 · 2024: $463 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.13 | 2021-2025 | |
| Glaxosmithkline, LLC. | $325.64 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $310.87 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $174.16 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $105.64 | 2021 | |
| Amarin Pharma, INC. | $84.62 | 2021 | |
| Eisai INC. | $63.11 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.36 | 2021-2023 | Trintellix |
| Amgen INC. | $57.14 | 2021-2022 | |
| Exact Sciences Corporation | $36.74 | 2024-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $34.96 | 2023-2024 | Quviviq |
| Halozyme INC | $34.01 | 2023 | |
| Galderma Laboratories, L.P. | $33.46 | 2024 | |
| Novartis Pharmaceuticals Corporation | $25.21 | 2024 | |
| Merz North America, INC. | $25.09 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.57 | 2024 | Xarelto |
| Solta Medical, A Division of Bausch Health US, LLC | $22.05 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $19.86 | 2021 | |
| Dexcom, INC. | $19.45 | 2023 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $18.41 | 2022 | |
| Seqirus USA INC | $16.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.